Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 23;17(11):1456-65.
doi: 10.1038/nm.2462.

Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia

Affiliations

Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia

Séverine Coulon et al. Nat Med. .

Abstract

Anemia because of insufficient production of and/or response to erythropoietin (Epo) is a major complication of chronic kidney disease and cancer. The mechanisms modulating the sensitivity of erythroblasts to Epo remain poorly understood. We show that, when cultured with Epo at suboptimal concentrations, the growth and clonogenic potential of erythroblasts was rescued by transferrin receptor 1 (TfR1)-bound polymeric IgA1 (pIgA1). Under homeostatic conditions, erythroblast numbers were increased in mice expressing human IgA1 compared to control mice. Hypoxic stress of these mice led to increased amounts of pIgA1 and erythroblast expansion. Expression of human IgA1 or treatment of wild-type mice with the TfR1 ligands pIgA1 or iron-loaded transferrin (Fe-Tf) accelerated recovery from acute anemia. TfR1 engagement by either pIgA1 or Fe-Tf increased cell sensitivity to Epo by inducing activation of mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling pathways. These cellular responses were mediated through the TfR1-internalization motif, YXXΦ. Our results show that pIgA1 and TfR1 are positive regulators of erythropoiesis in both physiological and pathological situations. Targeting this pathway may provide alternate approaches to the treatment of ineffective erythropoiesis and anemia.

PubMed Disclaimer

Comment in

References

    1. Blood. 1976 Sep;48(3):449-55 - PubMed
    1. Nat Med. 2010 Feb;16(2):177-82 - PubMed
    1. Immunity. 2005 Jan;22(1):31-42 - PubMed
    1. Blood. 1993 Oct 15;82(8):2340-52 - PubMed
    1. Cell Metab. 2008 Mar;7(3):205-14 - PubMed

Publication types

MeSH terms